98%
921
2 minutes
20
SMARCA4-deficient undifferentiated carcinoma (SMARCA4-DUC) of the stomach is a rare gastric tumor that has been receiving increased attention in recent years. With its varied pathological presentations, accurate diagnosis can be challenging. In order to improve our understanding of this aggressive neoplasm, we have carefully documented and analyzed 4 patients with gastric SMARCA4-DUC, adding to the overall knowledge of this uncommon malignancy. The patients were all men, with an average age of 69 years (range 57-76 years). The tumors were located in the gastric antrum (2 patients), the gastric body (1 patient), and the cardia (1 patient). Microscopically, the 3 surgical specimens exhibited similar morphological features: large to medium sized tumor cells, round, irregular to epithelioid undifferentiated cells in solid sheets or discohesive nests, with no obvious stromal reaction. In one patient, short spindle cells arranged in reticular, pseudopapillary, and disorderly patterns were observed amidst extensive interstitial edema. Some areas displayed a lymphoma-like starry sky phenomenon. The biopsy specimens showed large cells diffusely distributed in the submucosa, presenting pale pink cytoplasm, fine chromatin, and prominent large red nucleoli resembling melanoma. All 4 patients demonstrated BRG1 (SMARCA4) loss, INI1 (SMARCB1) retention, and focal positivity for epithelial markers (AE1/AE3 or epithelial membrane antigen). Three patients had clinically advanced (stages IIIC-IV) disease. Follow-up revealed that 1 patient deceased within 4.8 months. This article expands the morphological spectrum of this cancer, providing new insights for accurate cancer diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10668969241291884 | DOI Listing |
Front Oncol
August 2025
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York City, NY, United States.
Introduction: Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) is a recently described type of lung cancer, presenting as a bulky mass variably involving the mediastinum and the lung in patients with smoking history, and exhibits adverse prognosis. The essential diagnostic immunomorphologic features and typical genomic findings have been described. However, there is a continuing need to catalogue the spectrum of genomic changes underlying the disease, the heterogeneity of antigen expression in order to avoid diagnostic pitfalls, and any variability in patient outcomes.
View Article and Find Full Text PDFCancers (Basel)
August 2025
Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Osaka, Japan.
SMARCA4-deficient or SMARCA4-mutated cancers are rare but highly aggressive tumors with poor differentiation, resistance to conventional treatments, and limited clinical guidance. While thoracic SMARCA4-deficient undifferentiated tumors are relatively well described, the full spectrum of SMARCA4-altered cancers across different organs and their therapeutic responses remains poorly understood. This study aimed to systematically review published case reports and case series to clarify the clinical characteristics, molecular features, treatment patterns, and survival outcomes of SMARCA4-altered malignancies.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
August 2025
Department of Medical Oncology, Mie University Hospital, 2-174, Tsu, 514- 8507, Mie, Japan.
Purpose: The estimation of the primary site is crucial when considering chemotherapy regimens in cancer of unknown primary (CUP). The task is particularly challenging for poorly differentiated or undifferentiated carcinoma, or unknown histological tumors with unknown primary (U-CUP). Instead of site-specific chemotherapy, a biomarker-guided therapy using genomic testing is required to predict the efficacy of molecular-targeted agents and immune checkpoint inhibitors (ICI).
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
August 2025
Department of Medical Oncology, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
Background: SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-UT) is a rare and highly aggressive malignancy characterized by early distant metastasis and a poor prognosis, with a median overall survival (OS) of only 4-7 months. Traditional therapies offer limited benefit, while emerging data suggest the efficacy of combined immunotherapy, chemotherapy, and anti-angiogenic approaches. We report a case of a 52-year-old male with a heavy smoking history who presented with loss of consciousness and limb convulsions.
View Article and Find Full Text PDFOncologist
August 2025
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Background: SMARCA4-deficient thoracic tumors (SDTTs) mainly include SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-dUT) and SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC). Comparative studies between these subtypes remain limited, and no standardized therapeutic guidelines have been established.
Materials And Methods: This study retrospectively analyzed 102 patients with SDTT from January 2020 to May 2024.